Overview

Long-term Follow-up Study to Evaluate Durability of Sustained Virologic Response (SVR) in Previous GSK3228836 Study Participants (B-Sure)

Status:
Not yet recruiting
Trial end date:
2029-01-25
Target enrollment:
Participant gender:
Summary
This is a long-term follow-up study to assess durability of efficacy, as measured by SVR, in participants who have received prior treatment with GSK3228836 and achieved a complete or partial response. No further treatment with GSK3228836 will be administered in this study.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline